CTLA4 and neoplasm: A “triple threat” immunotherapy approach that includes OX40 stimulation may help augment the efficacy of dual PD-1/CTLA-4 blockade by enhancing the expansion, survival, and cytolytic activity of tumor-reactive effector T cells.